Correction: Invasive Breast Cancer Incidence in 2,305,427 Screened Asymptomatic Women: Estimated Long Term Outcomes during Menopause Using a Systematic Review.

There is an error in Table 2. The trial name, WHI II Prempro, in the ninth row is incorrect. The correct trial name is: WHI II Premarin. Please see the correct Table 2 here.

Table 2

Percent screened Peri/Postmenopausal Women Diagnosed with 1st Incident Invasive Breast Cancer in 19 published Studies.

#	Trial	Number of Women	Baseline Age	Years Studied	Number with Breast Cancer	Incidence [Percent]
1	UK Million Women Study [18]	1,084,110	50–64	2.6	9364	0.86%
2	Danish Nurses Health [19]	10,874	>44	6	244	2.24%
3	Melbourne Postmenopausal [20]	13,444	40–69	10	336	2.50%
4	Finnish Registry ERT [21]	110,980	>50	8	2171	1.96%
5	Finnish Registry E&P [22]	221,551	>50	11	6211	2.80%
6	French Cohort [23]	3175	>50	13	105	3.31%
7	WHI I Prempro [24]	8506	50–79	5.2	166	1.95%
7	WHI I Placebo [24]	8102	50–79	5.2	124	1.53%
8	WHI II Premarin [25]	5310	50–79	7.1	104	1.96%
8	WHI II Placebo [25]	5429	50–79	7.1	133	2.45%
9	Sweden: The Gothenburg Breast Screening Trial [26]	51,611	39–59	14	1509	2.92%
10	UK Trial of Early Detection of Breast Cancer [10]	39,773	45–64	7	459	1.15%
11	Australia Record Review of Postmenopausal Women [27]	508	35–84	5.8	7	1.38%
12	Osteoporosis Fracture Study [28]	9704	>65	3.2	117	1.21%
13	Italy ORDET [29]	4040	40–69	3.5	25	0.62%
14	NYU Postmenopausal [30]	7063	35–65	5.5	121	1.71%
15	US Breast Cancer Demonstration Detection Program [31]	283,222	40–93	3.5	4275	1.51%
16	Sweden-Malmo [32]	42,283	45–69	25	2316	5.47%
17	Norwegian Cohorts [33]	229,256	50–64	6	3997	1.74%
18	Swedish Two-Country Trial: Active Screened Group [34]	77,052	40–74	7	1398	1.81%
19	Canadian National Breast Screening Study [35]	89,434	40–59	7	1332	1.49%
	Total Numbers	2,305,427			34,514
	Mean Breast Cancer Incidence Calculation		34,514/2,205.427 ————→			1.50%